GlaxoSmithKline has settled nearly 25,000 cases over its Avandia diabetes drug in mediation as the MDL nears its end.
In November, U.S. District Judge Cynthia Rufe appointed a mediator to preside over settlement negotiations. In doing so, she a set a 75-day deadline to resolve 85 percent of the remaining cases. It was unclear whether lawyers met the threshold, but Rufe applauded the effort as “a major success,” according to Bloomberg.
The judge said that the remaining cases will be resolved through litigation.
The settlements are part of GSK’s efforts to resolve legal issues stretching back more than a decade. The drugmaker stated in November that it will pay $3 billion to settle U.S. criminal and civil probes into whether it illegally marketed Avandia and other medications.
The MDL is being held in Philadelphia, but GSK still has cases pending in state courts around the U.S. So far, as many as 50,000 cases have been resolved, including claims filed in both state and federal court, Diane Nast, a plaintiffs’ attorney who serves on a group helping to oversee cases, told Bloomberg.
In 2010, GSK agreed to stop promoting Avandia worldwide after studies linked the drug to increased risks of heart attacks. The company has since agreed to pay at least $700 million to settle more than 15,000 patients’ claims that the drug caused heart attacks and strokes.